Carteolol
Carteolol is a non-selective beta blocker used to treat glaucoma. It is administered in the form of eye drops.
Carteolol was patented in 1972 and approved for medical use in 1980.Pharmacology
Pharmacodynamics
Carteolol is a beta blocker, or an antagonist of the β-adrenergic receptors. It is selective for the β1-adrenergic receptor and has intrinsic [sympathomimetic activity]. Carteolol has also been found to act as a serotonin 5-HT1A and 5-HT1B receptor antagonist in addition to being a beta blocker.Pharmacokinetics
Carteolol is classified as a beta blocker with low lipophilicity and hence lower potential for crossing the blood–brain barrier. This in turn may result in fewer effects in the central [nervous system] as well as a lower risk of neuropsychiatric side effects.Chemistry
The experimental log P of carteolol is 1.1 and its predicted log P ranges from 0.99 to 2.39. It is a hydrophilic or low-lipophilicity beta blocker.Society and culture
Brand names of carteolol include Arteolol, Arteoptic, Calte, Cartéabak, Carteol, Cartéol, Cartrol, Elebloc, Endak, Glauteolol, Mikelan, Ocupress, Poenglaucol, Singlauc, and Teoptic.